Exelixis: growth far beyond its economy.
- Industry
- Biological Products,
- Headquarters
- United States
- Ticker
- EXEL (Nasdaq)
- Sources
- SEC filings (2000–2026), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
- Data as of
- November 8, 2026
- From profit to six straight losses. Exelixis lost money every year from 2013 to 2016: $1 billion in all. 2017 was its first profit in seven years: $0.2 billion.
- It outgrew its own economy many times over. Revenue rose from $0 billion in fiscal 2016 to $2.3 billion in fiscal 2026: 62.4 times as much. The US economy, counted the same way in money terms, grew about 65%. Whatever drove it, the economy around it does not account for growth of that size.
- Ahead of almost everyone like it. From 2016 to 2025, its revenue grew 1115% in US dollars; the median among 586 large manufacturers grew 58%. It outgrew 97% of them.
- Leaders came and went. Exelixis filed 31 leadership changes since 2016, more than 81% of large manufacturers (the median is 20). The day after each, its shares moved a median 0.2 points against its sector. The news was rarely news.
Financial results
| Fiscal year | Revenue | Net income | |
|---|---|---|---|
| 2016 | $0 billion | −$0.2 billion | |
| 2016 | $0.2 billion | −$0.1 billion | |
| 2016 | $0.2 billion | −$0.1 billion | |
| 2017 | $0.5 billion | $0.2 billion | |
| 2018 | $0.9 billion | $0.7 billion | |
| 2020 | $1 billion | $0.3 billion | |
| 2021 | $1 billion | $0.1 billion | |
| 2021 | $1.4 billion | $0.2 billion | |
| 2022 | $1.6 billion | $0.2 billion | |
| 2023 | $1.8 billion | $0.2 billion | |
| 2025 | $2.2 billion | $0.5 billion | |
| 2026 | $2.3 billion | $0.8 billion |
As reported in its annual filings. Losses in red.
Has Exelixis had layoffs?
Headcount, as reported
| Annual report | Employees | As of |
|---|---|---|
| 10-K for 2023 | 1,310 | December 31, 2023 |
| 10-K for 2025 | 1,147 | December 31, 2024 |
| 10-K for 2026 | 1,077 | December 31, 2025 |
Job cuts, severance and restructuring
Exelixis announced and implemented a restructuring plan that reduced its employee workforce.
“In January 2024, we announced and implemented a restructuring plan, including a reduction of our employee workforce by approximately 175 employees, or 13% of our total headcount.” 10-K for 2023
Exelixis plans to exit part of its laboratory space in the Greater Philadelphia area as part of the restructuring plan approved in early 2024.
“We anticipate exiting approximately 40,000 square feet of our laboratory space in the Greater Philadelphia area as part of our restructuring plan approved in early 2024.” 10-K for 2023
The restructuring plan was also intended to reduce real estate commitments and costs and terminate certain licensing partnerships; the accounting impact was still being evaluated.
“In January 2024, our Board of Directors authorized, and we implemented, a corporate restructuring plan intended to reduce our workforce and rebalance our cost structure in alignment with our strategic priorities, including reducing real estate commitments and costs, and terminating certain licensing partnerships.” 10-K for 2023
Announced and implemented a restructuring plan that reduced the employee workforce by about 175 employees, or 13% of total headcount.
“In January 2024, we announced and implemented a restructuring plan, including a reduction of our employee workforce by approximately 175 employees, or 13% of our then total headcount.” 10-K for 2025
Authorized a corporate restructuring plan (the 2024 Restructuring Plan) to reduce workforce and rebalance cost structure, including reducing real estate commitments and terminating certain licensing partnerships.
“In January 2024, we announced that our Board of Directors had authorized a corporate restructuring plan (the 2024 Restructuring Plan) to reduce our workforce and rebalance our cost structure in alignment with our strategic priorities, including reducing real estate commitments and costs, and terminating certain licensing partnerships.” 10-K for 2025
Recorded total restructuring costs under the 2024 Restructuring Plan, including severance and employee-related costs, contract termination costs and impairment.
“The total restructuring costs, incurred during the year ended December 31, 2024, associated with the 2024 Restructuring Plan were $ 33.7 million and were recorded to the restructuring expense line item within our Consolidated Statements of Income as they were incurred through the end of the plan.” 10-K for 2025
Exited two leases in the Greater Philadelphia area covering about 40,000 square feet and recognized a non-cash impairment charge.
“In connection with the restructuring plan, we recognized $ 12.7 million of non-cash impairment charge during the year ended December 31, 2024, to reduce the carrying value of these long-lived assets at their fair value.” 10-K for 2025
Terminated certain in-licensing collaboration arrangements as part of the 2024 Restructuring Plan.
“As part of the 2024 Restructuring Plan (as defined below), we have terminated certain of our in-licensing collaboration arrangements, including Aurigene Oncology, Ltd., BioInvent International AB, Cybrexa Therapeutics LLC, NBE-Therapeutics AG and STORM Therapeutics LTD.” 10-K for 2025
In August 2025 the company adopted and carried out a corporate reorganization plan to reorganize its workforce and close its King of Prussia, Pennsylvania office.
“In August 2025, our Board of Directors authorized, and we implemented, a corporate reorganization plan (the 2025 Plan) to reorganize our workforce and close our office located in King of Prussia, Pennsylvania.” 10-K for 2026
The 2025 reorganization plan cost $20.5 million in total, mostly severance and employee-related costs, recorded in 2025.
“The total restructuring costs, incurred during the year ended December 31, 2025, associated with the 2025 Plan were $ 20.5 million and are presented in the restructuring expense line item within our Consolidated Statements of Income.” 10-K for 2026
In January 2024 the company adopted and carried out a restructuring plan to cut its workforce and rebalance its cost structure.
“In January 2024, our Board of Directors authorized, and we implemented, a corporate restructuring plan (the 2024 Plan) to reduce our workforce and rebalance our cost structure in alignment with our strategic priorities.” 10-K for 2026
The 2024 restructuring plan cost $33.7 million in expenses in 2024.
“The total restructuring costs, incurred during the year ended December 31, 2024, associated with the 2024 Plan were $ 33.7 million in expenses and were recorded to the restructuring expense line item within our Consolidated Statements of Income as they were incurred through the end of the plan.” 10-K for 2026
As part of the 2024 restructuring plan, the company gave up about 40,000 square feet of office and laboratory space in the Greater Philadelphia area in 2025.
“In 2025, we exited approximately 40,000 square feet of our office and laboratory space in the Greater Philadelphia area as part of our 2024 corporate restructuring plan.” 10-K for 2026
| Fiscal year ended | Restructuring charges | Cash paid for restructuring |
|---|---|---|
| 2016-12-31 | $914,000 | $4.6 million |
| 2017-12-29 | −$32,000 | — |
| 2018-12-28 | $0 | — |
| 2022-12-30 | $0 | — |
| 2023-12-29 | $0 | — |
| 2025-01-03 | $33.7 million | — |
| 2026-01-02 | $20.5 million | $17.7 million |
Exelixis filed 1 restructuring notice (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
What has Exelixis acquired?
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
Iconic (rights to anti-TF antibodies)“In January 2022, we announced an amendment to our agreement with Iconic, which we entered into in December 2021, to acquire broad rights to use the anti-TF antibody used in XB002 for any application, including conjugated to other payloads, as well as rights within oncology to a number of other anti-TF antibodies developed by Iconic, including for use in ADCs and multispecific biotherapeutics.” 10-K for 2023 | acquisition | January 2022 | — |
Basecamp Bio Inc.“In August 2025, we entered into an asset purchase agreement with Basecamp Bio Inc. (Basecamp Bio), under which we acquired all right, title and interest in Basecamp Bio’s program directed at SSTR2, an oncology target that is highly expressed in NET.” 10-K for 2026 | acquisition | August 2025 | — |
Deal filings since 2016
- 2019-12-19 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2019-04-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-07-20 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-05-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-02-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2017-01-31 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-12-21 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-08-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2016-08-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Who are Exelixis's competitors?
Who Exelixis names
| Company | Named in |
|---|---|
| AstraZeneca PLC | 2026 |
| Genzyme | 2026 |
| Merck & Co. | 2026 |
| MSN Pharmaceuticals, Inc. | 2026 |
| Teva | 2026 |
In its own words
AstraZeneca PLC
“Should the combination of zanzalintinib and nivolumab be approved for the treatment of these RCC patients, we believe its principal competition may include AstraZeneca PLC’s savolitinib + durvalumab vs. Pfizer’s sunitinib and similar approved therapies or therapies in late-stage development that compete with cabozantinib or combination regimens containing cabozantinib in various RCC indications.” 10-K for 2026
Genzyme
“We believe that the principal competing anti-cancer therapy to COMETRIQ in progressive, metastatic MTC is Genzyme’s vandetanib, which has been approved by the FDA and the EC for the treatment of symptomatic or progressive MTC in patients with unresectable, locally advanced, or metastatic disease, as well as other therapies that have been recently approved to treat patients with advanced or metastatic RET-mutant MTC who require systemic therapy, including: Blueprint Medicines’ and Roche’s pralsetinib; and Eli Lilly’s selpercatinib.” 10-K for 2026
Merck & Co.
“We believe the principal competition for CABOMETYX in advanced RCC includes: the combination of Merck & Co.’s pembrolizumab and Pfizer’s axitinib; the combination of BMS’s ipilimumab and nivolumab; the combination of Merck & Co.’s pembrolizumab and Eisai’s lenvatinib; the combination of Eisai’s lenvatinib and Novartis’ everolimus; and Merck & Co.’s belzutifan.” 10-K for 2026
MSN Pharmaceuticals, Inc.
“For example, other companies, including MSN Pharmaceuticals, Inc.” 10-K for 2026
Teva
“In the longer term, we may eventually face competition from potential manufacturers of generic or follow-on versions of our marketed products, including the proposed generic versions of CABOMETYX tablets that are the subject of ANDAs submitted to the FDA by MSN, Teva, Cipla, Biocon and Sun, as well as the 505(b)(2) for cabozantinib capsules submitted by Handa, or the 505(b)(2) for cabozantinib tablets submitted to the FDA by Azurity.” 10-K for 2026
What are Exelixis's subsidiaries?
Subsidiaries it lists
| Subsidiary | Jurisdiction |
|---|---|
| Exelixis Patent Company LLC | Delaware |
| Exelixis Plant Sciences, Inc. | Delaware |
| Exelixis U.S., LLC | Delaware |
From Exhibit 21 of the 10-K for 2026. Companies must list their significant subsidiaries there and may leave out smaller ones, so this is the company’s own list, not every entity it owns.
Layoffs, acquisitions, competitors and subsidiaries are read from Exelixis’s annual reports (10-K for 2026, 10-K for 2025, 10-K for 2023), as of 2026-02-10.
Everything behind these findings, ready for your board deck.
- Market reaction to disclosed decisions: 41 decision filings since 2016, each linked to the SEC, with the share return against its sector and the US market the next day and the next year (32 with market data).
- Economic context: 7 measures for the United States, every year since 2016, from the official sources.
- Peer comparison: against 953 companies of its size in its sector.
- Financial results: ten years of revenue, operating and net income, and every annual report, linked.
- Methods and sources, so each number can be checked and cited.
The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.
More from Stratrix
The Business Model Wizard
Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.
Free · about twelve minutesBuild your Model Thesis →Test a decision, free
Set a live decision against the companies that made it before you.
AcquisitionsThe Distance TestDivestituresThe Divestiture TestDiversificationThe Diversification TestMake or buyThe Make-or-Buy TestWeekly email
Stratonomics, every Tuesday
One data story every Tuesday: what happened, what it means, and the figures you can quote. Free.